Nanalysis Scientific Corp. Announces $160 Million Multi Year Contract Win

Rhea-AI Summary

Nanalysis Scientific Corp. announced a six-year contract valued at $160 million with the Canadian Air Transportation Security Authority (CATSA) to provide service and maintenance for security screening equipment. This contract, effective from May 25, 2022, may be renewed for an additional five years, creating a potential eleven-year recurring revenue opportunity. The project’s phase-in process is underway, targeting completion by the end of Q1 2023. This win is expected to enhance Nanalysis's footprint in the security vertical and contribute to shareholder value.

Positive

• Secured a $160 million contract with CATSA for six years, with potential five-year renewal.
• Contract provides a material recurring revenue stream bolstering financial stability.
• Expands Nanalysis's presence in the security market, potentially leading to future growth.
• Anticipates completion of service coverage by end of Q1 2023, boosting operational efficiency.

Negative

• None.

CALGARY, AB, May 26, 2022 /PRNewswire/ - Nanalysis Scientific Corp. (TSXV:NSCI, OTCQX:NSCIF, FRA:1N1) ("Nanalysis" or the "Company") announces that the Company's wholly-owned subsidiary K'(Prime) Technologies (KPrime) has won a six year $160 million service and maintenance contract with Canadian Air Transportation Security Authority ("CATSA"), which includes a gradual phase in period of approximately one year. Furthermore, it is common for these types of contracts to be renewed for an additional five years, making it a potential 11 year recuring revenue opportunity, with inflation-based contractual price increases. The effective date of the executed contract is May 25, 2022 and it expires on May 31, 2028.

"We are pleased to have won this contract to support imaging and other security screening equipment at all airports across Canada," said Sean Krakiwsky, Founder and Chief Executive Officer of Nanalysis. "The security market is a very important vertical for all our products, including benchtop NMR, and it is our vision to have direct sales and service capabilities in every major market in the world. This contract win is an instrumental step in simultaneously opening up the security vertical as well as adding a material recurring revenue stream to our business. In addition to world-class R&D and manufacturing, we are now a world-class equipment service provider. We expect to expand this business in the security vertical, globally, as part of our growth plans going forward."

KPrime has begun the phase in process for this project to airports across Canada, and the company anticipates the service coverage to be completed before the end of Q1, 2023.

Martin Corrigan, Vice President and CTO of CATSA states: "We look forward to working with KPrime as they assume the maintenance service responsibilities for our of large fleet of screening equipment across the country."

Kham Lin, Founder and President of KPrime and Managing Director of Nanalysis' Security Business, states: "We have been positioning KPrime to win this contract for several years but needed to be part of a larger organization to conduct business of this size. This contract win is one example of how Nanalysis + KPrime will enable larger business opportunities and value creation for shareholders. We currently provide service in airports and other security markets, and so we are well positioned to expand this business. This business also opens sales channels for Nanalysis' proprietary products going forward. Because of our experience with these types of service contracts, we are very confident in our ability to successfully implement and profitably manage this world-class project."

Airports, border crossings, prisons, and other security markets are expected to be important growth drivers for Nanalysis over the next five years and beyond. Nanalysis' vision is to build a fully vertically integrated global scientific instrumentation company, serving customers in the security, pharma, biotech, food, energy, advanced materials, petrochemical, healthcare, and education markets with imaging and detection products and service. The company will continue to expand direct sales, service, and channel management capabilities world-wide, and will also strengthen technology partnerships, as well as develop important supply chain risk-mitigation and technology differentiation capabilities as geo-political landscape evolves, ensuring the ability to continue to drive growth and create shareholder value.

About Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA:1N1)

Nanalysis trades on the TSX Venture Exchange (TSXV) in Canada with ticker symbol 'NSCI', OTC and the Frankfurt exchange under the ticker symbol '1N1'. The company's business is what we term "MRI and NMR for industry". The company develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers or analyzers for laboratory and industrial markets. The NMReady-60™ was the first full-feature portable NMR spectrometer in a single compact enclosure requiring no liquid helium or any other cryogens. The company has followed-up that initial offering with new products and continues to have a strong innovation pipeline. Nanalysis recently announced that it has begun selling a 100MHz device in 2020. The Company's new device will be the most powerful and most advanced compact NMR device ever brought to market.

Nanalysis devices are used in many industries (oil and gas, chemical, mining, pharma, biotech, flavor and fragrances, agrochemicals, law enforcement, and more) as well as numerous government and university research labs around the world. The Company continues to exploit new global market opportunities independently and with partners.

With the recent acquisition of K'(Prime) Technologies Inc. (KPrime), the company maintains a North American sales and service company of over 40 individuals who cover scientific instrumentation for pharma, food, chemical and oil & gas customers, as well as imaging systems for security applications.

Additionally, the Company has a 43% ownership in Quad Systems AG ("Quad Systems"), with an option to purchase the remaining shares. Quad Systems is a Zurich-based Nuclear Magnetic Resonance (NMR) company focused on high-field NMR for pharmaceutical and other vertical markets.

Notice regarding Forward Looking Statements and Legal Disclaimer

This news release contains forward-looking statements and forward-looking information (collectively "forward-looking information") within the meaning of applicable securities laws pertaining to the following: : the expected revenue from the CATSA contract over five years and the renewal of the CATSA contract for an additional five years. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. The forward-looking information is based on certain key expectations and assumptions made by the Company's management which may prove to be incorrect, including but not limited to: the ability of the Company to implement and manage the CATSA contract. The Company believes the expectations reflected in these forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking statements in this news release should not be unduly relied upon. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company's disclosure documents on the SEDAR website at www.sedar.com. These risks and uncertainties include, but are not limited to: risks and uncertainties relating to the  management's ability to anticipate and manage the factors and risks referred to therein. Forward-looking information included in this news release are made as of the date of this news release and such information should not be relied upon as representing its views as of any date subsequent to the date of this news release. The Company has attempted to identify important factors that could cause actual results, performance or achievements to vary from those current expectations or estimates expressed or implied by the forward-looking information. However, there may be other factors that cause results, performance or achievements not to be as expected or estimated and that could cause actual results, performance or achievements to differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation. 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nanalysis-scientific-corp-announces-160-million-multi-year-contract-win-301555828.html

SOURCE Nanalysis Scientific Corp.

FAQ

What is the value of the contract won by Nanalysis Scientific Corp. with CATSA?

Nanalysis Scientific Corp. won a contract valued at $160 million.

How long is the contract with CATSA effective for Nanalysis?

The contract is effective for six years, with potential for a five-year renewal.

When did the contract with CATSA become effective?

The contract became effective on May 25, 2022.

What is the expected completion date for the service coverage project in Canada?

The service coverage project is expected to be completed by the end of Q1 2023.